Encompass Health Corporation EHC

Encompass Health Corp. (NYSE: EHC) today announced plans to expand inpatient rehabilitation capacity in the greater Houston area through two projects in Montgomery County, Texas: the Company's first small-format inpatient rehabilitation hospital in Conroe and a replacement hospital for its existing inpatient rehabilitation hospital in The Woodlands.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at outpatient & specialty care stocks, starting with Encompass Health (NYSE:EHC).

Today, Encompass Health, the nation's largest owner and operator of inpatient rehabilitation hospitals, announced the opening of Encompass Health Rehabilitation Hospital of Lower Providence in Lower Providence Township in Montgomery County, Pennsylvania. The 50-bed inpatient rehabilitation hospital is now accepting patients.

On August 5, Encompass Health (NYSE:EHC) reported second quarter results that beat its own expectations by enough to raise full year guidance twice in the same release, first on revenue and then on profit. Net operating revenue climbed 9.6% to $1.597 billion, and adjusted earnings per share rose 10.7% to $1.55. For the largest owner […]

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

Encompass Health (EHC) has put a fresh financing framework in place, filing an omnibus shelf registration that covers potential future offerings of common and preferred stock, warrants and debt securities. See our latest analysis for Encompass Health. Encompass Health shares have eased in the past week following the shelf registration and recent $100 million senior notes issuance, although a 30 day share price return of 6.57% and a 3 year total shareholder return of 77.79% indicate momentum...

Encompass Health is back in focus as analysts edge their price targets higher, with fair value estimates moving from about US$145.25 to roughly US$148.17. Much of this shift traces to recent Q2 results, updated 2026 guidance, and a wave of research that now clusters price targets in the US$144 to US$150 range. As you read on, you will see what is driving these revisions and how to track the next moves in the Encompass Health story. Stay updated as the Fair Value for Encompass Health shifts by...

Encompass Health stock has more than doubled over the past 5 years, yet current checks still suggest the shares trade at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and to what earnings multiples imply. Encompass Health has returned about 105.2% over 5 years, which puts current investors in the position of weighing further upside against the gains already on the table. Expectations for continued cash flow generation from its rehabilitation...